CY1123464T1 - Διαμορφωση δραστικοτητας επιδερμικου αυξητικου παραγοντα δεσμευσης-ηπαρινης για την επουλωση της τυμπανικης μεμβρανης - Google Patents

Διαμορφωση δραστικοτητας επιδερμικου αυξητικου παραγοντα δεσμευσης-ηπαρινης για την επουλωση της τυμπανικης μεμβρανης

Info

Publication number
CY1123464T1
CY1123464T1 CY20201100675T CY201100675T CY1123464T1 CY 1123464 T1 CY1123464 T1 CY 1123464T1 CY 20201100675 T CY20201100675 T CY 20201100675T CY 201100675 T CY201100675 T CY 201100675T CY 1123464 T1 CY1123464 T1 CY 1123464T1
Authority
CY
Cyprus
Prior art keywords
heparin
healing
effectiveness
modulation
tympanic membrane
Prior art date
Application number
CY20201100675T
Other languages
English (en)
Inventor
Peter Luke Santa Maria
Yunzhi Peter YANG
Sungwoo Kim
Chloe DOMVILLE-LEWIS
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of CY1123464T1 publication Critical patent/CY1123464T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0076—Sprayable compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • A61F11/20—Ear surgery
    • A61F11/202—Surgical middle-ear ventilation or drainage, e.g. permanent; Implants therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/18—Internal ear or nose parts, e.g. ear-drums
    • A61F2002/183—Ear parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Abstract

Παρέχονται συνθέσεις και μέθοδοι για τη δημιουργία ή τη θεραπεία χρόνιας διάτρησης τυμπανικής μεμβράνης με διαμόρφωση της δραστικότητας HB-EGF.
CY20201100675T 2013-05-15 2020-07-23 Διαμορφωση δραστικοτητας επιδερμικου αυξητικου παραγοντα δεσμευσης-ηπαρινης για την επουλωση της τυμπανικης μεμβρανης CY1123464T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361823749P 2013-05-15 2013-05-15
PCT/US2014/033536 WO2014186075A2 (en) 2013-05-15 2014-04-09 Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing

Publications (1)

Publication Number Publication Date
CY1123464T1 true CY1123464T1 (el) 2022-03-24

Family

ID=51898980

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100675T CY1123464T1 (el) 2013-05-15 2020-07-23 Διαμορφωση δραστικοτητας επιδερμικου αυξητικου παραγοντα δεσμευσης-ηπαρινης για την επουλωση της τυμπανικης μεμβρανης

Country Status (27)

Country Link
US (3) US20160074476A1 (el)
EP (2) EP3708181A1 (el)
JP (1) JP6316943B2 (el)
KR (1) KR102318748B1 (el)
CN (2) CN105555296A (el)
AU (2) AU2014265901B2 (el)
BR (2) BR112015028367B1 (el)
CA (1) CA2912411C (el)
CY (1) CY1123464T1 (el)
DK (1) DK2996709T3 (el)
ES (1) ES2805002T3 (el)
HK (1) HK1217166A1 (el)
HR (1) HRP20200971T1 (el)
HU (1) HUE049294T2 (el)
IL (2) IL242454B (el)
LT (1) LT2996709T (el)
MX (2) MX2015015774A (el)
PH (2) PH12015502577B1 (el)
PL (1) PL2996709T3 (el)
PT (1) PT2996709T (el)
RS (1) RS60412B1 (el)
RU (2) RU2676483C2 (el)
SG (1) SG11201509347UA (el)
SI (1) SI2996709T1 (el)
UA (1) UA120037C2 (el)
WO (1) WO2014186075A2 (el)
ZA (1) ZA201508289B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102634748B1 (ko) 2018-06-15 2024-02-13 삼성전자주식회사 포토 마스크용 펠리클 및 이의 제조 방법
MX2022001374A (es) 2019-07-31 2022-03-17 Astellas Pharma Inc Composicion farmaceutica para administracion otica.
JPWO2022065404A1 (el) 2020-09-25 2022-03-31

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
AU3124793A (en) 1991-10-29 1993-06-07 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US6514533B1 (en) * 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
AU725654B2 (en) 1996-05-03 2000-10-19 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
AU9785598A (en) 1997-10-03 1999-04-27 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
US6191109B1 (en) * 1997-10-31 2001-02-20 Children's Hospital, Inc. Methods of treating intestinal ischemia using heparin-binding epidermal growth factor
JP2002512200A (ja) * 1998-04-17 2002-04-23 アンジオジェニックス， インコーポレイテッド 治療的な脈管形成因子およびその使用方法
CA2395902A1 (en) 1999-12-28 2001-07-05 Asger Lau Dalmose Dual chamber syringe with a dual function piston
AU2001239549A1 (en) 2000-03-24 2001-10-03 Akzo Nobel N.V. Keratinocyte growth inhibitors and hydroxamic acid derivatives
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US20090148486A1 (en) * 2005-04-28 2009-06-11 Helen Lu Compositions and methods for treating pulp inflammations caused by infection or trauma
US20070038298A1 (en) * 2005-06-30 2007-02-15 Sulner Joseph W Repair of tympanic membrane using placenta derived collagen biofabric
JP4839476B2 (ja) 2005-09-28 2011-12-21 国立大学法人 鹿児島大学 ヘパリン結合性上皮増殖因子様増殖因子の新規医薬用途
WO2008134635A1 (en) 2007-04-30 2008-11-06 Nationwide Children's Hospital Heparin binding epidermal growth factor (hb-egf) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation
US20090192079A1 (en) * 2007-10-09 2009-07-30 Genzyme Corporation Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen
EP2249863A4 (en) * 2008-01-22 2011-12-28 Omnio Healer Ab METHOD OF ENHANCING WOUND HEALING
US8822410B2 (en) * 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof
AU2009263249B2 (en) * 2008-06-26 2015-03-19 Nobelpharma Co., Ltd. Agent for regenerating tympanic membrane or external auditory canal
AU2010285974A1 (en) * 2009-08-17 2012-03-22 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
WO2011103382A2 (en) * 2010-02-22 2011-08-25 The Brigham And Women's Hospital Compositions and methods for inducing angiogenesis
US8556854B2 (en) 2010-07-22 2013-10-15 Becton, Dickinson And Company Dual chamber syringe with retractable needle
US9763777B2 (en) 2011-07-11 2017-09-19 Ear Science Institute Australia Device for ear drum repair
US9821118B2 (en) 2011-09-02 2017-11-21 Unl Holdings Llc Automatic reconstitution for dual chamber syringe
JP6456285B2 (ja) * 2012-06-28 2019-01-23 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 選択的重合性組成物およびｉｎｖｉｖｏでのその使用方法
JP2016525374A (ja) 2013-04-09 2016-08-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 架橋キトサン−ラクチドヒドロゲル

Also Published As

Publication number Publication date
WO2014186075A2 (en) 2014-11-20
IL242454B (en) 2020-05-31
CA2912411A1 (en) 2014-11-20
PT2996709T (pt) 2020-07-14
EP2996709A4 (en) 2016-11-16
US20160074476A1 (en) 2016-03-17
CA2912411C (en) 2022-10-25
EP3708181A1 (en) 2020-09-16
MX2015015774A (es) 2016-07-26
US11235027B2 (en) 2022-02-01
IL273329A (en) 2020-04-30
DK2996709T3 (da) 2020-06-02
HK1217166A1 (zh) 2016-12-30
BR122020011229B1 (pt) 2022-06-07
BR112015028367B1 (pt) 2020-12-01
AU2019200630A1 (en) 2019-02-21
PH12015502577A1 (en) 2016-02-29
SG11201509347UA (en) 2015-12-30
JP2016520080A (ja) 2016-07-11
UA120037C2 (uk) 2019-09-25
WO2014186075A3 (en) 2015-06-04
PL2996709T3 (pl) 2021-02-08
RU2676483C2 (ru) 2018-12-29
AU2019200630B2 (en) 2020-08-27
EP2996709A2 (en) 2016-03-23
JP6316943B2 (ja) 2018-04-25
EP2996709B1 (en) 2020-05-06
BR112015028367A2 (pt) 2017-07-25
KR20160013063A (ko) 2016-02-03
MX2020001319A (es) 2020-03-20
KR102318748B1 (ko) 2021-10-27
CN113559242A (zh) 2021-10-29
PH12020551126A1 (en) 2021-12-13
SI2996709T1 (sl) 2020-09-30
US20180256684A1 (en) 2018-09-13
IL273329B (en) 2021-05-31
LT2996709T (lt) 2020-08-10
RS60412B1 (sr) 2020-07-31
RU2015148636A (ru) 2017-06-20
US11963998B2 (en) 2024-04-23
CN105555296A (zh) 2016-05-04
US20220111006A1 (en) 2022-04-14
HUE049294T2 (hu) 2020-09-28
RU2018146249A (ru) 2019-01-18
HRP20200971T1 (hr) 2020-10-02
ES2805002T3 (es) 2021-02-10
ZA201508289B (en) 2019-02-27
PH12015502577B1 (en) 2016-02-29
AU2014265901B2 (en) 2018-11-08
AU2014265901A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
CY1122981T1 (el) Συνθεσεις για διαμορφωση της εκφρασης του c9orf72
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1124998T1 (el) Ετεροκυκλικες ενωσεις και χρήσεις αυτων
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1124299T1 (el) Συνδυαστικες θεραπειες που περιλαμβανουν μορια αντισωματων κατα toy lag-3
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
CY1124805T1 (el) Φλαγγελινη roseburia και ανοσοτροποποιηση
CL2018002782A1 (es) Apósito modificado
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
CY1123464T1 (el) Διαμορφωση δραστικοτητας επιδερμικου αυξητικου παραγοντα δεσμευσης-ηπαρινης για την επουλωση της τυμπανικης μεμβρανης
BR112015032224A2 (pt) anticorpos anti-fcrh5
UY35464A (es) Inhibidores covalentes de kras g12c.
CY1123716T1 (el) Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη
UY4234Q (es) Configuración aplicada en zapato
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도